阿加曲班联合依达拉奉治疗急性脑梗死疗效分析

Analysis of the efficacy of Argatroban combined with Edaravone in the treatment of acute cerebral infarction

目的观察阿加曲班联合依达拉奉治疗急性脑梗死的临床疗效。方法选择2011-05—2013-05于我院就诊的76例急性脑梗死患者,随机分为实验组40例和对照组36例,对照组给予单纯的阿加曲班药物治疗,实验组在此基础上联用依达拉奉治疗。观察治疗前后2组患者的神经功能缺损的改善情况及生活质量评分改善情况,比较2组临床疗效,评估用药的不良反应。结果 2组治疗后神经功能恢复较好,生活质量评分也较前改善,差异有统计学意义(P<0.05),且实验组的评分改善情况明显较对照组好,差异有统计学意义(P<0.05);实验组有效率95.00%,明显优于对照组的77.78%,差异有统计学意义(χ2=4.92,P<0.05);2组患者服药后凝血指标均有不同程度的延长,但无明显差异(P>0.05),且均未出现严重出血等不良反应。结论阿加曲班联合依达拉奉可明显改善急性脑梗死的神经功能缺损症状,提高患者生存质量,且无明显不良反应,适合临床推广应用。

Objeetive To analyze the effect of Argatroban combined with Edaravone on acute cerebral infarction. Methods 76 patients with acute cerebral infarction were selected from May 2011 to May 2013 in our hospital, then they were randomly divided into experimental group of 40 patients and control group of 36 patients, the control group was given Argatroban, the experimental group was given Argatroban combined with Edaravone. And then we observed nerve function of two groups be- fore and after treatment and compared the efficiency of the treatment and drug reactions. Results After treatment, recovery of neurological function and quality of life scores improved than those before treatment, the difference was statistically significant （P^0.05）. The experimental group score improvement was significantly better than that of the control group （P〈0.05） ; the effective rate of experimental group was 95.00%, also significantly better than the control group with treatment efficiency of 77.78% （X2 =4.92, P〈0.05） ; After treatment, clotting time was prolonged, but had no significant difference （P〈0.05）. Conclusion Argatroban combined with Edaravone may be a good improvement for acute cerebral infarction.